Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis

Luatti, Simona; Castagnetti, Fausto; Marzocchi, Giulia; Baldazzi, Carmen; Gugliotta, Gabriele; Iacobucci, Ilaria; Specchia, Giorgina; Zanatta, Lucia; Rege‐Cambrin, Giovanna; Mancini, Marco; Abruzzese, Elisabetta; Zaccaria, Alfonso; Grimoldi, Maria Grazia; Gozzetti, Alessandro; Ameli, Gaia; Capucci, Maria Adele; Palka, Giandomenico; Bernasconi, Paolo; Palandri, Francesca; Pane, Fabrizio; Saglio, Giuseppe; Martinelli, Giovanni; Rosti, Gianantonio; Baccarani, Michele; Testoni, Nicoletta

doi:10.1182/blood-2011-10-384651

Cited by 101 publications

(62 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A high-risk score and a CCA/Ph+, so-called major route [30,31], are significant predictors of a poorer response to TKIs and of a poorer outcome. There are three risk scores, Sokal [32], EURO [33], and EUTOS [34].…”

Section: The Definition Of the Risk Baselinementioning

confidence: 99%

A review of the European LeukemiaNet recommendations for the management of CML

et al. 2015

Self Cite

View full text Add to dashboard Cite

Several guidelines and recommendations on the management of chronic myeloid leukemia (CML) have been prepared by several scientific societies. The European LeukemiaNet (ELN) appointed a panel of experts who submitted their recommendations to peer-reviewed scientific journals in 2006, 2009, and 2013. Here, we make a critical review of the last, 2013, ELN recommendations, concerning the use of the five available tyrosine kinase inhibitors (TKIs), the evaluation of cytogenetic and molecular response, and the strategy of treatment. Three TKIs (imatinib, nilotinib, dasatinib) are recommended first-line. Bosutinib and ponatinib are available second-line; ponatinib is particularly indicated in case of the T315I mutation. Achieving an optimal response, not only for survival but also for a deeper, stable, treatment-free remission, requires a BCR-ABL transcripts level ≤ 10 % at 3 months, ≤ 1 % at 6 months, ≤ 0.1 % at 1 year, and ≤ 0.01 % later on. Molecular monitoring must include mutational analysis in every case of failure. A successful treatment of accelerated and blastic phase requires TKIs, and in many cases also allogeneic stem cell transplantation.

show abstract

Section: The Definition Of the Risk Baselinementioning

confidence: 99%

A review of the European LeukemiaNet recommendations for the management of CML

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…1&2). It is reported that sole cytogenetic abnormalities have received attention because the term sole refers not only to the first cytogenetic changes to occur in neoplastic cells, but also their important role in tumorigenesis [3,7].…”

Section: Resultsmentioning

confidence: 99%

Trisomy 19 as the Sole Chromosomal Abnormality in CML

Vaniawala¹

2014

IJGG

View full text Add to dashboard Cite

Abstract:Presence of trisomy 19 in chronic myeloid leukemia (CML) normally considered as secondary abnormality but trisomy 19 rarely occur as sole abnormality. In the present study a total of 2312 Ph positive CML were screened from year2004 to 2014 and we found 2 cases of trisomy 19 as sole karyotype abnormalities. Both karyotype showed 47,XY,t(9;22)(q34;q11.2),+19,complements. It is not known that which gene(s) present on chromosome 19 plays important role in development of this condition.

show abstract

“…Recent studies have reported that major route abnormalities such as trisomy 8 at diagnosis were related to a worse outcome t(9,22) [20,21].…”

Section: Discussionmentioning

confidence: 99%

“…Both monosomy 7 and del (7p) are of the additional chromosomal abnormalities and they associated with adverse prognostic factors in CML patients treated with IM as a frontline therapy [19,20].…”

Section: Discussionmentioning

confidence: 99%

A novel cytogenetic abnormality r(7)(::p11.2->q36.3::) in a Philadelphia-positive chronic myeloid leukemia case

Achkar¹,

Wafa²,

Aljapawe³

et al. 2013

CRCM

View full text Add to dashboard Cite

The so-called Philadelphia (Ph) chromosome is present in more than 90% of chronic myeloid leukemia (CML) cases. It results in juxtaposition of the 5' part of the BCR gene on chromosome 22 and the 3' part of the ABL1 gene on chromosome 9. An additional acquired monosomy 7 or deletion of 7q is associated with poor prognosis in a variety of myeloid disorders. Here we report a novel Ph chromosome positive CML case with a ring chromosome 7 [r(7)]. Immunophenotyping was compatible with CML, although 4.5% of total leucocytes appeared like acute myelogeneous leukemia (AML) subtype M2. The r(7) was characterized in detail by array-proven multicolor banding (aMCB), the latter being of enormous significance to characterize breakpoint regions in detail. Underlying mechanisms and prognostic are discussed, as ring chromosomes are rare cytogenetic abnormalities in hematopoietic malignancies.

show abstract

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis

Cited by 101 publications

References 44 publications

A review of the European LeukemiaNet recommendations for the management of CML

A review of the European LeukemiaNet recommendations for the management of CML

Trisomy 19 as the Sole Chromosomal Abnormality in CML

A novel cytogenetic abnormality r(7)(::p11.2->q36.3::) in a Philadelphia-positive chronic myeloid leukemia case

Contact Info

Product

Resources

About

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis

Cited by 101 publications

References 44 publications

A review of the European LeukemiaNet recommendations for the management of CML

A review of the European LeukemiaNet recommendations for the management of CML

Trisomy 19 as the Sole Chromosomal Abnormality in CML

A novel cytogenetic abnormality r(7)(::p11.2-&gt;q36.3::) in a Philadelphia-positive chronic myeloid leukemia case

Contact Info

Product

Resources

About

A novel cytogenetic abnormality r(7)(::p11.2->q36.3::) in a Philadelphia-positive chronic myeloid leukemia case